Related Experiment Video
Updated: Nov 28, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Acarbose ameliorates spontaneous type‑2 diabetes in db/db mice by inhibiting PDX‑1 methylation
Diyi Zhou1, Lijun Chen1, Xin Mou1
1Department of Endocrinology, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, Zhejiang 310000, P.R. China.
Abstract:
Pancreatic and duodenal homeobox (PDX)‑1 is a gene that plays an important role in pancreatic development and function. Type‑2 diabetes mellitus (T2DM) is a metabolic disease associated with insulin resistance and impaired islet β‑cell function. There is evidence that methylation of PDX‑1 plays a role in the development of T2DM. Acarbose is an α‑glucosidase inhibitor that can effectively delay the absorption of glucose by the body. The aim of the present study was to examine the effect of acarbose on PDX‑1 methylation in islet β‑cells in spontaneous type‑2 diabetic db/db mice. The effect of acarbose on glucose and lipid metabolism in these mice was assessed by measuring food intake, body weight, glycated hemoglobin (HbA1c), glucagon, serum total cholesterol and triglyceride levels, and fasting blood glucose (FBG). Blood glucose levels were also analyzed using intraperitoneal glucose tolerance and insulin tolerance tests. Immunohistochemistry was used to evaluate the effect of acarbose on pathological changes in the pancreas. Moreover, a BrdU assay was used to analyze cell proliferation. Lastly, the effect of acarbose on PDX‑1 methylation was evaluated in mice using methylation‑specific PCR and western blot analysis. In the present study, body weight significantly increased in the acarbose group, compared to the normal group. The levels of HbA1c and glucagon in the T2DM group significantly increased, compared with the normal group, but significantly decreased in acarbose‑treated mice. Moreover, FBG levels significantly decreased in the acarbose groups compared with T2DM mice. Acarbose also promoted cell proliferation, compared with untreated T2DM mice. In addition, PDX‑1 methylation and cytoplasmic expression levels were both downregulated in the acarbose group, compared with the T2DM group. In conclusion, these results suggested that acarbose could promote the proliferation of islet β‑cells and inhibit PDX‑1 methylation in islet β cells from diabetic mice. Thus, acarbose may provide a new strategy to treat T2DM.
Insights
Acarbose treatment in diabetic mice reduced PDX-1 methylation and improved islet beta-cell function. This suggests acarbose may offer a novel therapeutic strategy for type-2 diabetes mellitus.
Area of Science:
- Endocrinology
- Molecular Biology
- Pharmacology
Background:
- Type-2 diabetes mellitus (T2DM) involves insulin resistance and impaired islet beta-cell function.
- PDX-1 gene methylation is implicated in T2DM development.
- Acarbose, an alpha-glucosidase inhibitor, delays glucose absorption.
Purpose of the Study:
- To investigate the effect of acarbose on PDX-1 methylation in islet beta-cells of diabetic db/db mice.
- To assess acarbose's impact on glucose and lipid metabolism and pancreatic changes in T2DM mice.
Main Methods:
- Assessment of metabolic parameters (body weight, HbA1c, glucagon, lipids, FBG) and glucose/insulin tolerance tests.
- Immunohistochemistry for pancreatic pathology, BrdU assay for cell proliferation.
- Methylation-specific PCR and Western blot to evaluate PDX-1 methylation and expression.
Main Results:
- Acarbose treatment decreased HbA1c, glucagon, and fasting blood glucose levels in diabetic mice.
- Acarbose promoted islet beta-cell proliferation and downregulated PDX-1 methylation and cytoplasmic expression.
- While body weight increased, overall metabolic control and beta-cell function markers improved.
Conclusions:
- Acarbose inhibits PDX-1 methylation in islet beta-cells of diabetic mice.
- Acarbose promotes islet beta-cell proliferation, suggesting a potential therapeutic role in T2DM.
- These findings highlight acarbose as a potential new strategy for managing type-2 diabetes mellitus.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones

